Free Trial

Jasper Therapeutics (JSPR) Stock Forecast & Price Target

$23.19
-1.13 (-4.65%)
(As of 06/18/2024 ET)

Jasper Therapeutics - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Consensus Price Target

$64.29
177.21% Upside
High Forecast$80.00
Average Forecast$64.29
Low Forecast$40.00
TypeCurrent Forecast
6/20/23 to 6/19/24
1 Month Ago
5/21/23 to 5/20/24
3 Months Ago
3/22/23 to 3/21/24
1 Year Ago
6/20/22 to 6/20/23
Consensus Rating
Buy
Buy
Buy
Buy
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
9 Buy rating(s)
9 Buy rating(s)
6 Buy rating(s)
4 Buy rating(s)
Hold
0 Hold rating(s)
0 Hold rating(s)
0 Hold rating(s)
0 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$64.29$64.29$62.50$62.13
Forecasted Upside177.21% Upside222.34% Upside296.11% Upside303.04% Upside
Get Jasper Therapeutics Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for JSPR and its competitors with MarketBeat's FREE daily newsletter.

JSPR Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

JSPR Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Jasper Therapeutics Stock vs. The Competition

TypeJasper TherapeuticsMedical CompaniesS&P 500
Consensus Rating Score
3.00
2.70
2.50
Consensus RatingBuyModerate BuyHold
Predicted Upside177.21% Upside1,068.18% Upside11.31% Upside
News Sentiment RatingPositive News
Positive News
Positive News
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
6/18/2024Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingOverweight
5/15/2024HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
E. Bodnar
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$65.00+202.75%
4/3/2024Evercore ISI
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageOutperform$65.00+148.09%
3/28/2024Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageOutperform$70.00+142.89%
3/18/2024TD Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageOutperform
3/7/2024Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingOutperform ➝ Outperform$80.00+197.40%
11/8/2023William Blair
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingOutperform
8/14/2023Credit Suisse Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingOutperform ➝ Outperform$40.00+200.75%
8/11/2023Capital One Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
T. Chiang
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOverweight$70.00+396.45%
3/9/2023EF Hutton Acquisition Co. I
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingBuy$68.50+262.43%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Wednesday at 06:07 AM ET.

JSPR Forecast - Frequently Asked Questions

What is Jasper Therapeutics's stock forecast and purchase recommendation?

According to the research reports of 9 Wall Street equities research analysts, the average twelve-month stock price forecast for Jasper Therapeutics is $64.29, with a high forecast of $80.00 and a low forecast of $40.00. The consensus rating for Jasper Therapeutics stock is Buy based on the current 9 buy ratings for JSPR. Learn more on JSPR's analyst rating history.

Do Wall Street analysts like Jasper Therapeutics more than its competitors?

Analysts like Jasper Therapeutics more than other "medical" companies. The consensus rating for Jasper Therapeutics is Buy while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how JSPR compares to other companies.

Does Jasper Therapeutics's stock price have much upside?

According to analysts, Jasper Therapeutics's stock has a predicted upside of 209.07% based on their 12-month stock forecasts.

What analysts cover Jasper Therapeutics?

Jasper Therapeutics has been rated by research analysts at Cantor Fitzgerald, Evercore ISI, HC Wainwright, and Royal Bank of Canada in the past 90 days.


Stock Forecasts and Research Tools

This page (NASDAQ:JSPR) was last updated on 6/19/2024 by MarketBeat.com Staff

From Our Partners